{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=87",
    "query": {
      "condition": "Multiple Myeloma",
      "page": 87
    },
    "page_size": 10
  },
  "pagination": {
    "page": 87,
    "page_size": 10,
    "total_count": 2319,
    "total_pages": 232,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=88&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=86&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T01:44:06.350Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05317416",
      "title": "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 854,
      "start_date": "2022-03-25",
      "completion_date": "2029-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317416"
    },
    {
      "nct_id": "NCT00182663",
      "title": "Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "clarithromycin",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2003-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00182663"
    },
    {
      "nct_id": "NCT02890758",
      "title": "Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Myeloproliferative Syndromes",
        "Plasma Cell Myeloma",
        "Colon Carcinoma",
        "Adenocarcinoma of Rectum",
        "Soft Tissue Sarcoma",
        "Ewing's Sarcoma",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Natural Killer (NK) Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Brenda Cooper, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-05-22",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890758"
    },
    {
      "nct_id": "NCT00104104",
      "title": "A Multiple Myeloma Trial in Patients With Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2004-10",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2011-06-29",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 68,
      "location_summary": "Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104104"
    },
    {
      "nct_id": "NCT05976555",
      "title": "Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Maximum tolerated dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-05-15",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05976555"
    },
    {
      "nct_id": "NCT00998049",
      "title": "Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2009-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-05-14",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998049"
    },
    {
      "nct_id": "NCT04661137",
      "title": "A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Selinexor 60 MG",
          "type": "DRUG"
        },
        {
          "name": "Selinexor 80 MG",
          "type": "DRUG"
        },
        {
          "name": "Selinexor 100 MG",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2021-03-16",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04661137"
    },
    {
      "nct_id": "NCT06904066",
      "title": "Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignancy, Hematologic",
        "Neoplasms, Hematologic",
        "Neoplasms, Hematopoietic",
        "Blood Cancer",
        "Hematological Neoplasms",
        "Hematopoietic Malignancies",
        "Dysmyelopoietic Syndromes",
        "Hematopoetic Myelodysplasia",
        "Myeloid Leukemia, Acute",
        "Nonlymphoblastic Leukemia, Acute",
        "Leukemia, Lymphocytic, Acute"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Individual Patient TCR-Transduced PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TruSight Oncology (TSO) 500",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 86,
      "start_date": "2026-10-28",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06904066"
    },
    {
      "nct_id": "NCT02092922",
      "title": "A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Filanesib, KSP (Eg5) inhibitor; intravenous",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2014-05",
      "completion_date": "2017-09-05",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092922"
    },
    {
      "nct_id": "NCT05192122",
      "title": "Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Discontinue maintenance therapy SOC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-12-31",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-08T01:44:06.350Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05192122"
    }
  ]
}